Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Conditions

Osteosarcoma 4Lymphoma 3Renal Insufficiency 2Neurotoxicity Syndromes 2Mucositis 2Lymphoma, Large B-Cell, Diffuse 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × glucarpidase × Clear all
NCT00219791 2014-09-11

Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance

BTG International Inc.

Phase 2 Completed

Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡